Vimal Mehta insider trades: BioXcel Therapeutics (BTAI) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Vimal reports to the SEC
Open-market buys and sales
19 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| May 20, 2026 | BTAI | ↓ Sell | 19,419 | $1.09 | $21K | Direct | May 22, 2026 (2d) |
| Dec 16, 2024 | BTAI | ↓ Sell | 3,117 | $0.36 | $1K | Direct | Dec 17, 2024 (1d) |
| Sep 16, 2024 | BTAI | ↓ Sell | 1,982 | $0.69 | $1K | Direct | Sep 17, 2024 (1d) |
| Jun 17, 2024 | BTAI | ↓ Sell | 2,134 | $1.28 | $3K | Direct | Jun 18, 2024 (1d) |
| Jun 5, 2024 | BTAI | ↓ Sell | 252,028 | $1.61 | $405K | By BioXcel LLC | Jun 6, 2024 (1d) |
| Apr 4, 2024 | BTAI | ↓ Sell | 5,268 | $2.62 | $14K | Direct | Apr 8, 2024 (4d) |
| Jun 16, 2023 | BTAI | ↓ Sell | 60,000 | $20.86 | $1.3M | Direct | Jun 16, 2023 (0d) |
| May 22, 2023 | BTAI | ↓ Sell | 6,500 | $25.79 | $168K | Direct | May 24, 2023 (2d) |
| Mar 21, 2023 | BTAI | ↓ Sell | 64,500 | $18.97 | $1.2M | Direct | Mar 22, 2023 (1d) |
| Dec 16, 2022 | BTAI | ↓ Sell | 60,000 | $19.69 | $1.2M | Direct | Dec 19, 2022 (3d) |
| Jun 25, 2021 | BTAI | ↓ Sell | 473,250 | $30.83 | $14.6M | Indirect | Jun 29, 2021 (4d) |
| Aug 16, 2019 | BTAI | ↑ Buy | 974 | $8.89 | $9K | Direct | Aug 19, 2019 (3d) |
| Aug 15, 2019 | BTAI | ↑ Buy | 2,983 | $8.64 | $26K | Direct | Aug 16, 2019 (1d) |
| Aug 13, 2019 | BTAI | ↑ Buy | 1,000 | $8.75 | $9K | Direct | Aug 14, 2019 (1d) |
| Dec 14, 2018 | BTAI | ↑ Buy | 2,000 | $4.38 | $9K | Direct | Dec 14, 2018 (0d) |
| Dec 4, 2018 | BTAI | ↑ Buy | 1,000 | $5.12 | $5K | Direct | Dec 4, 2018 (0d) |
| Dec 3, 2018 | BTAI | ↑ Buy | 1,000 | $5.17 | $5K | Direct | Dec 4, 2018 (1d) |
| Nov 30, 2018 | BTAI | ↑ Buy | 1,000 | $5.10 | $5K | Direct | Nov 30, 2018 (0d) |
| Mar 12, 2018 | BTAI | ↑ Buy | 2,000 | $11.00 | $22K | By Spouse | Feb 16, 2021 (1072d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other BTAI insiders
Open-market trades in the last 12 months
About Vimal Mehta's insider trades
Vimal Mehta is CEO and President at BioXcel Therapeutics (BTAI). Since Mar 12, 2018, Vimal has reported 8 open-market purchases worth $89K and 11 sales worth $18.9M on SEC Form 4. In the last 12 months: 1 sale ($21K).
Their filings also include option exercises (19 filings), grants and awards (11 filings), other transactions (2 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every BTAI insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.